|
Gene: ZNF611 |
Gene summary for ZNF611 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF611 | Gene ID | 81856 |
Gene name | zinc finger protein 611 | |
Gene Alias | ZNF611 | |
Cytomap | 19q13.41 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8N823 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
81856 | ZNF611 | RNA-P17T-P17T-2 | Human | Lung | IAC | 4.46e-03 | 7.83e-01 | 0.3371 |
81856 | ZNF611 | RNA-P17T-P17T-8 | Human | Lung | IAC | 9.91e-03 | 6.41e-01 | 0.3329 |
81856 | ZNF611 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.48e-08 | 4.01e-01 | -0.0166 |
81856 | ZNF611 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.74e-06 | 3.24e-01 | -0.0132 |
81856 | ZNF611 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 1.42e-06 | 3.14e-01 | -0.013 |
81856 | ZNF611 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 3.13e-06 | 3.60e-01 | -0.0121 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Lung | AAH: Atypical adenomatous hyperplasia | |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF611 | SNV | Missense_Mutation | rs754302461 | c.1982N>A | p.Arg661His | p.R661H | Q8N823 | protein_coding | tolerated(0.45) | benign(0.028) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
ZNF611 | SNV | Missense_Mutation | novel | c.1086N>C | p.Arg362Ser | p.R362S | Q8N823 | protein_coding | deleterious(0) | benign(0.432) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZNF611 | SNV | Missense_Mutation | novel | c.1085N>A | p.Arg362Lys | p.R362K | Q8N823 | protein_coding | tolerated(0.09) | benign(0.07) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZNF611 | SNV | Missense_Mutation | novel | c.275N>T | p.Arg92Ile | p.R92I | Q8N823 | protein_coding | deleterious(0.02) | benign(0.103) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ZNF611 | SNV | Missense_Mutation | c.1925N>T | p.Arg642Ile | p.R642I | Q8N823 | protein_coding | tolerated(0.1) | benign(0.034) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF611 | SNV | Missense_Mutation | novel | c.1085N>T | p.Arg362Ile | p.R362I | Q8N823 | protein_coding | deleterious(0.02) | benign(0.156) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF611 | SNV | Missense_Mutation | rs747002319 | c.1028N>G | p.Tyr343Cys | p.Y343C | Q8N823 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF611 | SNV | Missense_Mutation | novel | c.7N>T | p.Arg3Cys | p.R3C | Q8N823 | protein_coding | deleterious(0.04) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
ZNF611 | insertion | Nonsense_Mutation | novel | c.248_249insTCTGGTGTTTCCTTAAG | p.Glu83AspfsTer6 | p.E83Dfs*6 | Q8N823 | protein_coding | TCGA-A5-A0R8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
ZNF611 | insertion | Frame_Shift_Ins | novel | c.687_688insA | p.Ser230IlefsTer5 | p.S230Ifs*5 | Q8N823 | protein_coding | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |